Pediatric Cancer in the 2000s: Uneven Survival Gains Seen Richard Mark Kirkner Cancer. 2026;132(13):e70505. doi:10.1002/cncr.70505

https://www.medscape.com/viewarticle/pediatric-cancer-2000s-uneven-survival-gains-seen-2026a1000mmc?src= Over the previous two decades, overall survival for children with cancer has improved unevenly. Survival gains varied by cancer, and the demographic factors of race and ethnicity, economic status, and zip code also seemed to be driving disparities in cancer survival, according to a large population analysis of a national database.

HER2-Mutated NSCLC: Are Your Clinical Decisions on Target? Authors: Nicolas Girard, MD, PhD

https://www.medscape.org/viewarticle/her2-mutated-nsclc-are-your-clinical-decisions-target-2026a10000gu?page=1&src=mkmcmr_driv_stan_mscpedu_260704-OUS-HONC-her2-mutated-nsclc-are-your-clinical-decisions-target-2026a10000gu-cta&uac=148436CN

Results From the VISIONARY Clinical Trial of Sibeprenlimab in Patients With IgA Nephropathy by Madaline Spencer| Published on: Jun 29, 2026

Results From the VISIONARY Clinical Trial of Sibeprenlimab in Patients With IgA Nephropathy by Madaline Spencer| Published on: Jun 29, 2026 Vlado Perkovic, MD, Professor of Medicine and Provost at the University of New South Wales Sydney, discusses results from the VISIONARY clinical trial testing Voyxact (sibeprenlimab) in patients with IgA nephropathy (IgAN). https://checkrare.com/results-from-the-visionary-clinical-trial-of-sibeprenlimab-in-patients-with-iga-nephropathy/

FDA Grants Full Approval to Afami-Cel for Patients With Synovial Sarcoma by Madaline Spencer| Published on: Jun 30, 2026

https://checkrare.com/fda-grants-full-approval-to-afami-cel-for-patients-with-synovial-sarcoma/ The US Food and Drug Administration (FDA) has granted full approval to Tecelra (afamitresgene autoleucel; afami-cel) and expanded its indication to include patients ages 12 years and older with unresectable or metastatic synovial sarcoma whose disease has progressed after chemotherapy. Eligible patients must be positive for HLA-A*02:01, -A*02:02, -A*02:03, or -A*02:06 and have tumors that express the MAGE-A4 antigen.

The Role of Rusfertide in Decreasing Phlebotomies in Patients With Polycythemia Vera by Madaline Spencer| Published on: Jul 1, 2026

The Role of Rusfertide in Decreasing Phlebotomies in Patients With Polycythemia Vera by Madaline Spencer| Published on: Jul 1, 2026 Andrew Kuykendall, MD, Clinical Researcher at Moffitt Cancer Center, discusses the role of rusfertide in decreasing phlebotomies in patients with polycythemia vera (PV). https://checkrare.com/the-role-of-rusfertide-in-decreasing-phlebotomies-in-patients-with-polycythemia-vera/

Congenital Adrenal Hyperplasia by CheckRare Staff| Updated on: Jul 1, 2026

https://checkrare.com/congenital-adrenal-hyperplasia/ Congenital adrenal hyperplasia (CAH) is a group of rare autosomal, recessive genetic disorders that impair production of cortisol (also known as hydrocortisone).[1,2] The hypothalmus and pituitary gland are prompted to overproduce corticotropin-releasing hormone (CRH) and adrenocorticotrophic hormone (ACTH), causing an abnormal enlargement of the adrenal gland and accumulation of cortisol precursors produced by the adrenal gland.[1] With the inability to convert these precursors to cortisol, the body converts them to androgens (i.e., male hormones) instead, resulting in excess androgen concentrations.[3]

Spinal Muscular Atrophy: The Changing Definition of Success by CheckRare Staff| Published on: Jul 1, 2026

Spinal Muscular Atrophy: The Changing Definition of Success by CheckRare Staff| Published on: Jul 1, 2026 An Expert Panel on the Evolution of SMA Care Spinal muscular atrophy (SMA) has undergone a remarkable transformation over the past decade. Drs. Nancy Kuntz, Alicia Henriquez, and Angela Lek discuss how advances in disease-modifying therapies have fundamentally changed the outlook for children living with SMA, leading clinicians to rethink what constitutes a successful outcome in SMA care. https://checkrare.com/spinal-muscular-atrophy-the-changing-definition-of-success/